Profile

Prof. Said Dermime is a highly experienced senior scientist in Cancer Immunology and Immunity with more than 30 years of expertise in the fields of academia and research. He also has over 25 years of experience in establishing research groups and/or departments. He obtained his Master and PhD degrees in immunology from Salford University, Manchester, UK in 1987 and 1992 respectively. After on, he joined the National Cancer Institute, Milan (Italy) from 1992-1994; then the NHLBI, NIH, Bethesda (USA) from 1995-1997 as postdoctoral fellow. After this he was appointed as a Leader of the Lymphoma-Cancer Vaccine Team at the Paterson Institute for Cancer Research, Christie Hospital, Manchester (UK) for a period of 5 years. After this period, he moved to King Faisal Specialist Hospital & Research Centre, Riyadh (KSA), as Senior Scientist, to establish and lead the Tumor Immunology Section for a period of 6 years. In 2008, he moved to Kuwait to establish the Department of Biomedical Research at Dasman Diabetes Institute as Department Chairman for a period of 4 years. In 2012, he joined King Fahad Specialist Hospital Dammam, Dammam (KSA) for a period of 3 years to establish and lead the department of Biomedical Research. In 2015, he joined the National Centre for Cancer Care and Research (NCCCR) at Hamad Medical Corporation, Doha (Qatar) to establish and direct the Translational Cancer Research Facility. Prof. Dermime has been recently appointed as a Clinical Professor of Biomedical Sciences at the Health Sciences Department of Qatar University, Doha, Qatar in addition to his current position at Hamad Medical Corporation. He has in-depth knowledge of designing therapeutic and prophylactic strategies and evaluating them in preclinical and clinical studies where he was able to develop complementary approaches with respect to immunological assays of tumor immunity and cancer vaccines and has been a major contributor to several scientific discoveries. He has published over 100 peer-reviewed articles in high impact factor journal such as Molecular Cancer (IF= 41.444), Blood (IF= 22.113), Seminars in Cancer Biology (IF= 17.012), Journal for Immunotherapy of Cancer (IF= 13.751), Cancer Research (IF= 12.701) , Clinical Cancer Research (IF= 12.531), , Journal of Experimental and Clinical Cancer Research (IF= 11.161), Frontiers in Immunology (IF= 8.786), and Cancers (IF= 6.639).